Thrombotic microangiopathy ( TMA ) related endpoints in these trials included the following:
2.
Bacterial toxins are the primary cause of one category of thrombotic microangiopathy known as HUS or hemolytic uremic syndrome.
3.
Initial therapy included the utilization of therapeutic plasma exchange, a mainstay initial treatment for TTP . However, Miller et al . reported no ADAMTS13 activity deficiency nor identifiable antibody to ADAMTS13 as seen in TTP indicating a thrombotic microangiopathy of different underlying etiology.
4.
The disease affects both children and adults and is characterized by systemic thrombotic microangiopathy ( TMA ), the formation of blood clots in small blood vessels throughout the body, which can lead to stroke, heart attack, kidney failure, and death.
5.
Both STEC-HUS and aHUS cause endothelial damage, leukocyte activation, platelet activation, and widespread inflammation and multiple thromboses in the small blood vessels, a condition known as systemic thrombotic microangiopathy ( TMA ), which leads to thrombotic events as well as organ damage / failure and death.
6.
Patients with HUS commonly exhibit the signs and symptoms of thrombotic microangiopathy ( TMA ), which can include abdominal pain, low platelet count, elevated lactate dehydrogenase LDH, a chemical released from damaged cells, and which is therefore a marker of cellular damage ) decreased haptoglobin ( indicative of the breakdown of red blood cells ) proteinuria ( indicative of kidney injury ), confusion, edema ( swelling ), nausea / vomiting, and diarrhea.
मोबाइल